Format

Send to

Choose Destination
J Small Anim Pract. 2017 Jul;58(7):403-407. doi: 10.1111/jsap.12675. Epub 2017 May 3.

Preliminary investigation of urine N-telopeptide concentration as a biomarker of bone resorption in dogs receiving glucocorticoids.

Author information

1
Department of Small Animal Internal Medicine, Pride Veterinary Centre, Derby, DE24 8HX, UK.
2
Department of Clinical Biochemistry, Viapath, King's College, London, UK.
3
School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington, UK.

Abstract

OBJECTIVES:

The influence of glucocorticoid therapy on bone resorption in dogs using a urine N-telopeptide assay was investigated.

MATERIALS AND METHODS:

Thirty-one dogs receiving oral glucocorticoids and 31 age-matched healthy control dogs were enrolled. Urine N-telopeptide concentration was measured using a commercially available immunoassay and results were expressed as a ratio against urinary creatinine concentration. Dogs receiving glucocorticoids were divided into three subgroups based on daily glucocorticoid dose and three subgroups based on treatment duration. Urine N-telopeptide concentration was then compared between groups.

RESULTS:

Urine N-telopeptide concentration was significantly higher in dogs receiving glucocorticoids compared to the control group.

CLINICAL SIGNIFICANCE:

This preliminary study demonstrates significant increase in urine N-telopeptide concentration in dogs receiving glucocorticoid therapy compared to control dogs. Further studies are needed to assess whether this increase in urine N-telopeptide concentration correlates with decreases in bone mineral density as has been identified in humans.

PMID:
28466603
DOI:
10.1111/jsap.12675
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center